Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Precigen, Inc. (PGEN)

1.4   0 (0%) 06-26 20:02
Open: 1.39 Pre. Close: 1.4
High: 1.45 Low: 1.3
Volume: 2,053,290 Market Cap: 291(M)
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.45 - 1.46 1.46 - 1.47
Low: 1.28 - 1.29 1.29 - 1.3
Close: 1.38 - 1.4 1.4 - 1.41

Technical analysis

as of: 2022-06-24 4:42:22 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.72     One year: 1.93
Support: Support1: 1.16    Support2: 0.97
Resistance: Resistance1: 1.47    Resistance2: 1.65
Pivot: 1.35
Moving Average: MA(5): 1.34     MA(20): 1.33
MA(100): 1.74     MA(250): 3.52
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 37.9     %D(3): 33
RSI: RSI(14): 53.2
52-week: High: 6.53  Low: 1.12
Average Vol(K): 3-Month: 1,200 (K)  10-Days: 1,355 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PGEN ] has closed below upper band by 38.5%. Bollinger Bands are 26.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 26 Jun 2022
Precigen to Participate in the 2022 HC Wainwright Global Investment Conference - GuruFocus.com

Thu, 23 Jun 2022
Many human genomes shaped by past events that caused sharp dips in the population - EurekAlert

Sun, 19 Jun 2022
Financial Comparison: Myovant Sciences (NYSE:MYOV) vs. Precigen (NASDAQ:PGEN) - Defense World

Sat, 18 Jun 2022
Precigen (NASDAQ:PGEN) Stock Price Crosses Below 200-Day Moving Average of $2.30 - Defense World

Thu, 16 Jun 2022
Largest study of domestic cat DNA identifies disease-causing variants in new breeds - EurekAlert

Mon, 06 Jun 2022
Is Precigen Inc (PGEN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 207 (M)
Shares Float 99 (M)
% Held by Insiders 11.8 (%)
% Held by Institutions 68.5 (%)
Shares Short 19,710 (K)
Shares Short P.Month 19,090 (K)

Stock Financials

EPS -0.57
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.62
Profit Margin (%) -88.8
Operating Margin (%) -75.9
Return on Assets (ttm) -14.7
Return on Equity (ttm) -110.9
Qtrly Rev. Growth 25.2
Gross Profit (p.s.) -0.03
Sales Per Share 0.5
EBITDA (p.s.) -0.32
Qtrly Earnings Growth 0
Operating Cash Flow -56 (M)
Levered Free Cash Flow -27 (M)

Stock Valuations

PE Ratio -2.48
PEG Ratio -1.3
Price to Book value 2.22
Price to Sales 2.78
Price to Cash Flow -5.19

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.